Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients

BACKGROUND: High-grade gliomas are among the most aggressive central nervous system primary tumors, with a high risk of recurrence and a poor prognosis. Re-operation, re-irradiation, chemotherapy are options in this setting. No-best therapy has been established. Bevacizumab was approved on the basis...

Descripción completa

Detalles Bibliográficos
Autores principales: Detti, Beatrice, Scoccianti, Silvia, Teriaca, Maria Ausilia, Maragna, Virginia, Lorenzetti, Victoria, Lucidi, Sara, Bellini, Chiara, Greto, Daniela, Desideri, Isacco, Livi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Radiotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370943/
https://www.ncbi.nlm.nih.gov/pubmed/34081269
http://dx.doi.org/10.1007/s11547-021-01381-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370943/
https://www.ncbi.nlm.nih.gov/pubmed/34081269
http://dx.doi.org/10.1007/s11547-021-01381-5

Ejemplares similares